What are the indications for cabozantinib?

Cabozantinib (Cabozantinib), as a multi-target tyrosine kinase inhibitor, has been widely used in the treatment of various types of cancer. The following are the main indications for cabozantinib:

1.Advanced renal cell carcinoma (RCC): Cabozantinib is approved for the treatment of advanced renal cell carcinoma. This was one of the earliest indications for cabozantinib approved. Cabozantinib inhibits the growth and angiogenesis of renal cell carcinoma cells and slows disease progression by inhibiting the activity of multiple receptor tyrosine kinases, including MET and VEGFR2.

2.Thyroid cancer (TC): Cabozantinib is also approved for the treatment of locally advanced or metastatic thyroid cancer. In thyroid cancer, cabozantinib inhibits tumor cells and angiogenesis by inhibiting the activity of multiple targets, including MET, VEGFR2, and RET.

3.Hepatocellular carcinoma (HCC): Cabozantinib is also approved to treat advanced hepatocellular carcinoma. In hepatocellular carcinoma, cabozantinib inhibits the proliferation and angiogenesis of tumor cells by inhibiting the activity of multiple targets, including MET, VEGFR2, and KIT.

4.And other types of cancer: In addition to the above indications, cabozantinib is also being studied in clinical trials to treat other types of cancer, such as gastric cancer, colorectal cancer, non-small cell lung cancer, etc. Although not yet approved for these indications, cabozantinib is a multi-target inhibitor with potential therapeutic effect in multiple cancer types.

In general, cabozantinib, as a targeted therapy, has been approved for the treatment of advanced renal cell carcinoma, thyroid cancer, and hepatocellular carcinoma. In these indications, cabozantinib has shown significant efficacy and provides patients with an effective treatment option. At the same time, cabozantinib also shows potential application prospects in the treatment of other types of cancer, but further research and clinical verification are needed.